Cuál es el precio por Vertex Pharmaceuticals Incorporated (VRTX)

Precio por Vertex Pharmaceuticals Incorporated (VRTX) es de$519.38

Cuál es la capitalización de mercado por Vertex Pharmaceuticals Incorporated (VRTX)

Capitalización de mercado por Vertex Pharmaceuticals Incorporated (VRTX) es $131.82B

Vertex Pharmaceuticals Incorporated (VRTX) Acciones en Circulación

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Año	Acciones en circulación	Cambiar
2026 (TTM)	253.90M	-0.70%
2025	255.70M	-0.70%
2024	257.50M	-0.08%
2023	257.70M	0.62%
2022	256.10M	-0.62%
2021	257.70M	-0.82%
2020	259.84M	1.21%
2019	256.73M	0.96%
2018	254.29M	2.18%
2017	248.86M	2.16%
2016	243.59M	1.14%
2015	240.84M	2.52%
2014	234.92M	4.49%
2013	224.83M	6.08%
2012	211.95M	3.44%
2011	204.89M	2.24%
2010	200.40M	15.67%
2009	173.26M	23.27%
2008	140.56M	8.97%
2007	128.99M	13.92%
2006	113.22M	26.87%
2005	89.24M	13.58%
2004	78.57M	2.03%
2003	77.00M	1.66%
2002	75.75M	1.73%
2001	74.46M	10.02%
2000	67.68M	0.00%

Año

Acciones en circulación

Cambiar

2026 (TTM)

253.90M

-0.70%

2025

255.70M

-0.70%

2024

257.50M

-0.08%

2023

257.70M

0.62%

2022

256.10M

-0.62%

2021

257.70M

-0.82%

2020

259.84M

1.21%

2019

256.73M

0.96%

2018

254.29M

2.18%

2017

248.86M

2.16%

2016

243.59M

1.14%

2015

240.84M

2.52%

2014

234.92M

4.49%

2013

224.83M

6.08%

2012

211.95M

3.44%

2011

204.89M

2.24%

2010

200.40M

15.67%

2009

173.26M

23.27%

2008

140.56M

8.97%

2007

128.99M

13.92%

2006

113.22M

26.87%

2005

89.24M

13.58%

2004

78.57M

2.03%

2003

77.00M

1.66%

2002

75.75M

1.73%

2001

74.46M

10.02%

2000

67.68M

0.00%

Empresa	Acciones en circulación	Diferencia	País
Argenx SE ARGX.US	62.19M	-75.51%	NL
CSL Limited CSL.AX	478.91M	88.62%	AU
Moderna, Inc. MRNA.US	396.00M	55.97%	US
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	0.00	-100.00%	BE

Empresa

Acciones en circulación

Diferencia

País